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Consequences and management of hyperphosphatemia in pa-
tients with renal insufficiency. Progressive renal insufficiency
leads to hyperphosphatemia, hypocalcemia, and secondary
hyperparathyroidism. Bone demineralization in secondary
hyperparathyroidism may induce fractures, while joint and
subcutaneous precipitations of calcium pyrophosphate limit
mobility, and may cause crippling. Strategies to preempt bone
and joint destruction in chronic kidney disease and end-stage
renal disease have focused on limiting dietary phosphorus,
intra-gut binding of ingested phosphorous, enhancing calcium
absorption, and limiting parathyroid hormone secretion. De-
ciding which regimen is most effective to meet these treatment
objectives challenges nephrologists; they often uncover conflict-
ing evidence about which abnormal metabolite should be the
prime treatment objective. Especially vexing is the question of
whether hypercalcemia is a cardiotoxic consequence of calcium-
based phosphate binders.
Chronic kidney disease inducing progressive decrease
in renal function is estimated by an expert committee of
the National Kidney Foundation [1] to occur in about 20
million individuals in the United States. Chronic renal
failure results in reduced synthesis of vitamin D by the
kidneys and increased retention of phosphorus. Distur-
bances in calcium and phosphorous metabolism in pa-
tients with chronic kidney disease (CKD) can result in
secondary hyperparathyroidism, along with ensuing bone
disease, soft tissue and vascular calcification, as well as
arterial stiffness and artherosclerosis [2]. This review will
focus on the consequences of secondary hyperparathy-
roidism in the context of CKD. The challenges in treating
altered mineral metabolism and the resulting renal and
cardiac complications will also be discussed.
CKD and secondary hyperparathyroidism
In patients with end-stage renal disease (ESRD),
kidney failure results in decreased secretion and in-
creased retention of phosphate. This causes hyperphos-
phatemia, a condition that results in the development
of secondary hyperparathyroidism and renal osteodys-
trophy. Secondary hyperparathyroidism is characterized
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by parathyroid gland hyperplasia and increased syn-
thesis of parathyroid hormone (PTH) [3]. Secondary
hyperparathyroidism is usually quadraglandular, and re-
sults from the combined effect of altered calcium phos-
phate metabolism and vitamin D production. In addition
to increased phosphate retention, patients with ESRD
have reduced production of active vitamin D, resulting in
hypocalcemia and increased PTH. Over time, these fac-
tors result in parathyroid gland hyperplasia, autonomous
production of PTH, and tertiary hyperparathyroidism [4].
Figure 1 outlines multiple factors involved in the patho-
genesis of secondary hyperparathyroidism, including low
levels of vitamin D, hypocalcemia, altered parathyroid
gland function, and skeletal resistance to PTH. High
levels of circulating PTH result in bone loss and other
systemic defects, such as cardiovascular complications
that increase mortality in patients with renal failure. The
metabolism of calcium, phosphorous, and vitamin D plays
an important role in secondary hyperparathyroidism.
Impaired renal production of 1,25-dihydroxyvitamin D
(calcitriol), the active hormonal form of vitamin D, con-
tributes to the generation and maintenance of secondary
hyperparathyroidism in patients with CKD [5]. Calcitriol
represses parathyroid cell proliferation and PTH syn-
thesis. CKD patients have reduced levels of calcitriol,
which results in high serum PTH levels [6]. Calcitriol
deficiency results in indirect secondary hyperparathy-
roidism due to decreased intestinal absorption of calcium.
The progression of CKD, as determined by glomeru-
lar filtration rates, is associated with decreased levels of
1,25-dihydroxyvitamin D and a corresponding increase
in PTH levels, as shown in Figure 2 [7]. In this report,
PTH levels were compared in 58 diabetic and 268 nondi-
abetic patients with serum creatinine levels >1.2 mg/dL.
Diabetic patients with creatinine clearance <70 mL/min
had lower PTH levels than did nondiabetic patients
(P = 0.003), as well as significant differences in serum
phosphorus, magnesium, and tubular resorption of phos-
phate. Serum glucose concentration in those with dia-
betes varied inversely with PTH, leading to the inference
that poor control of diabetes (hyperglycemia) may con-
tribute to development of hypoparathyroidism in patients
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Fig. 1. Pathogenesis of secondary hyperparathyroidism. Low levels of
calcitriol (vitamin D), hypocalcemia, altered PTH gland function, and
skeletal resistance to PTH contribute to the pathogenesis of secondary
hyperparathyroidism in ESRD patients.
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Fig. 2. Vitamin D levels and the progression of chronic kidney disease
(CKD) [6]. Patients with progressive CKD, as determined by glomeru-
lar filtration rates (GFR), have decreased levels of vitamin D and a
corresponding increase in parathyroid hormone (PTH) levels.
with diabetes and renal insufficiency. Indeed, treatment
with 1,25-dihydrovitamin D results in decreased PTH
gene transcription and, consequently, decreased PTH
production.
Low serum levels of calcium also result in the increased
stability of PTH mRNA, which increases the secretion
of PTH and parathyroid cell proliferation [8]. The ef-
fects of calcium on the parathyroid gland are mediated by
a membrane-bound calcium-sensing receptor. Increased
levels of serum phosphorus have similar effects in reg-
ulating PTH levels. The effects of low calcium levels
and high phosphorus levels regulate PTH levels post-
transcriptionally via the altered binding of cytosolic pro-
teins to the 3′-untranslated region of the PTH mRNA
[9].
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Fig. 3. Clinical consequences of secondary hyperparathyroidism. In-
creased risk of cardiovascular and bone disease arises as a result of
elevated PTH levels.
EFFECTS OF SECONDARY
HYPERPARATHYROIDISM
Secondary hyperparathyroidism occurs in patients
with CKD due to a combined effect of hyperphos-
phatemia, hypocalcemia, increased calcium phosphate
(Ca × P) product, and reduced synthesis of vitamin D.
Alterations in the metabolism of these minerals is a part
of an interrelated cascade that contributes to bone and
joint destruction [10]. Additional potential devastating
effects on the cardiovascular system, such as cardiovas-
cular calcification, are often seen in patients with ESRD
[3]. Figure 3 summarizes the clinical consequences of in-
creased PTH in renal bone disease (osteitis fibrosa, bone
pain, demineralization, and fractures) and increased car-
diovascular risk.
Bone and joint destruction
The altered calcium and phosphorous metabolism in
secondary hyperparathryroidism leads to bone deminer-
alization resulting in fractures of the joint [11]. Addition-
ally, subcutaneous deposits of calcium pyrophosphate
limit mobility in patients with CKD. PTH is normally
anabolic for bone, but excess levels result in catabolism
of bone [12]. In most patients with CKD, a functional
and usually actual excess of PTH destroys bone by stim-
ulating the action of osteoclasts, which act to dissolve
bone and cause pathologic fractures. Calcium pyrophos-
phate deposits in the joints of patients with CKD cause
arthropathy, crippling joint pain, and swelling accompa-
nied by osteoclast-induced erosion of bone. In children
and young adults with slowly progressive renal osteodys-
trophy, terminal distal phalangeal osteolysis and clubbing
are typical. Progressive bone dissolution may be clinically
silent until a minor injury produces a pathologic fracture
of the wrist, arm, or hip.
Friedman: Consequences and management of hyperphosphatemia S-3
0.01
0.1
1
10
100
An
nu
al
 m
or
ta
lit
y 
(%
)
25-34 35-44 45-54 55-64 65-74 75-84 >85
Age (years)
Dialysis Male
Dialysis Female
Dialysis Black
Dialysis White
GP Male
GP Female
GP Black
GP White
Reprinted with permission from Am J Kidney Dis 32 (5 Suppl 3):S112–
S119,1998.
Fig. 4. Cardiovascular mortality in CKD pa-
tients compared with their counterparts in the
general population (GP). Increased percent
annual mortality is seen in dialysis patients
regardless of age, sex, or ethnicity [12].
Cardiovascular calcification
Vascular calcification, a marker of atherosclerosis and
arterial stiffness, is commonly seen in dialysis patients,
and is a risk factor for mortality. A proposed mechanism
for accelerated coronary artery calcification is based on
the observation that ESRD patients with more coronary
calcification had reduced skeletal mass due to calcium
mobilization from the bone.
An epidemiologic report indicated increased cardio-
vascular mortality in dialysis patients compared with that
of the general population [13]. Among patients treated
by hemodialysis or peritoneal dialysis, the prevalence of
coronary artery disease is approximately 40%, and the
prevalence of left ventricular hypertrophy is approxi-
mately 75%. According to an earlier report by the same
group [14], approximately 9% per year die of cardiovas-
cular disease. Adjusting for age, gender, race, and the
presence or absence of diabetes, indicates that cardio-
vascular mortality in dialysis patients is 10 to 20 times
higher than in the general population. Also, cardiac fail-
ure is more common in chronic renal disease patients
than in the general population, and is an independent pre-
dictor of death in chronic renal disease. The prevalence
of cardiac failure in hemodialysis and peritoneal dialysis
patients is approximately 40%. Often it is difficult to
determine whether cardiac failure reflects left ventric-
ular dysfunction or extracellular fluid volume overload.
Figure 4 summarizes the results of this group’s experi-
ence, and shows increased annual mortality in subgroups
of patients with renal failure and on dialysis, compared
with their counterparts in the general population, regard-
less of age, gender, or ethnicity. Indeed, after stratification
for age, gender, race, and diabetes, cardiovascular mor-
bidity and mortality in dialysis patients were 10 to 20 times
higher compared with the general population. Cardiac
failure was also higher and seen in approximately 40% of
patients on hemodialysis and peritoneal dialysis. Coro-
nary artery calcification is thought to be a contributing
factor to this increased mortality. Metastatic calcification
in the heart and muscles of the lower extremities has been
reported in patients with secondary hyperparathyroidism
[15].
Using electron beam computed tomography (EBT),
Braun et al have suggested that cardiovascular calcifi-
cation in dialysis patients is a result of lower vertebral
bone mass, and not from altered calcium and phosphate
metabolism [16]. EBT is a noninvasive, extensively used
method to detect cardiac calcification in coronary arter-
ies of dialysis patients. The rate of calcification was stud-
ied in 49 chronic hemodialysis patients, compared with
102 nondialysis patients with documented or suspected
coronary artery disease (CAD). All individuals in this
study had undergone coronary angiography. A total of 30
axial slices with 30 mm distance between the slices was
used to measure the number of calcifications. The surface
area was measured; average and highest density values
obtained were used to calculate a quantitative coronary
artery calcium score. Hemodialysis patients had a 2.5- to
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Fig. 5. Elevated serum phosphorus levels is
associated with increased risk of mortality in
dialysis patients. Increased serum phosphate
(>6.5 mg/dL) in CKD patients is associated
with increased risk of mortality.
5-fold higher coronary artery calcium score that corre-
lated with a lower vertebral bone mass compared with
nondialysis patients. However, no correlation between
serum calcium, phosphate, or PTH levels with the cal-
cium score was seen. Progress in calcification was seen at
a 12-month follow-up of these patients. Higher calcium
scores correlated with lower vertebral bone mass in dial-
ysis patients.
Due to the prevalence of hyperphosphatemia in ESRD
patients, and the associated increased cardiovascular
mortality, Ganesh et al studied the mechanism mediat-
ing this risk. Data from two large random samples of pa-
tients on hemodialysis (N = 12,833) in the United States
were used to test the hypothesis that elevated serum phos-
phate contributes to cardiac causes of death [17]. A 2-
year follow-up for the relative risk (RR) of CAD, sudden
death, and other cardiac causes was determined with re-
spect to serum phosphorus, Ca × P product, and serum
PTH levels. High cardiovascular mortality was seen in
patients with elevated serum phosphate (>6.5 mg/dL),
compared with the low phosporus group (≤6.5 mg/dL).
Elevated levels of serum P, Ca × P product, and PTH
have been implicated in the altered control of phosphate
metabolism. Additionally, serum calcium and calcium-
based binders were not found to be risk factors for car-
diovascular mortality in this report.
TREATMENT GOALS
Because hyperphosphatemia and increased Ca × PO4
products are associated with increased mortality in
dialysis patients, it is important to effectively manage
and treat hyperphosphatemia and the resulting hyper-
parathyroidism in patients with CKD. The aim of the
strategy for prevention and treatment should be 3-fold:
to reduce hyperphosphatemia and the pathogenesis of
phosphate retention, restore synthesis of active vitamin
D, and bring the calcium concentration back to normal
levels.
Management of hyperphosphatemia
Increased risk of mortality and secondary hyper-
parathyroidism in dialysis patients occurs when the serum
phosphorous levels exceed 6.5 mg/dL and the Ca × P
product exceeds 72 mg2/dL2. Because of the morbid-
ity and mortality associated with patients with ESRD,
data available for serum phosphate were analyzed from
two large, random, cross-sectional studies of patients on
hemodialysis for at least 1 year. Data were analyzed for
patients in the United States Renal Data System, the
Case Mix Adequacy Study, and the Dialysis Morbidity
and Mortality Study Wave [18]. The relative risk (RR) of
death for patients with serum phosphorus greater than
6.5 mg/dL was 1.27 compared with those with serum
phosphorus levels between 2.4 and 6.5 mg/dL. The link
between higher risk of death and serum phosphorous con-
centration, however, was not uniform across all the quin-
tiles of serum phosphate analyzed. Figure 5 is a graphic
depiction of these data. Patients in the highest 2 quintiles
of serum phosphorus are at the greatest risk for mortality.
For example, patients in the serum phosphorus quintiles
of 6.6 to 7.8 mg/dL and 7.9 to 16.9 mg/dL are predicted to
have a mortality risk of 1.18 and 1.39, respectively. The
Ca × P product showed a mortality risk trend similar to
that seen with serum phosphorus. However, the analy-
sis of serum calcium in this study showed no correlation
with the relative risk of death. These observations have
resulted in recommendations that serum phosphorous be
controlled between 2.5 and 6.5 mg/dL, and the Ca × P be
maintained at less than 52 mg2/dL2 [18].
The most effective means of controlling hyperphos-
phatemia is managing dietary phosphorous intake. A
typical American diet provides approximately 1300 mg
of phosphorous daily from a protein-rich meal. The
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recommended dietary allowance for phosphorus is 700
mg/day. Increased dietary intake of phosphorus, com-
bined with elevated serum phosphorous levels resulting
from altered mineral metabolism in dialysis patients, are
associated with vascular and visceral calcification. A re-
cent study involving 63 dialysis patients showed the effec-
tiveness of dietary education in controlling hyperphos-
phatemia [19]. At the onset of the study, patients had
mean serum phosphorous levels >6 mg/dL. A significant
difference (P < 0.01) in serum phosphorus (6.8 ± 0.72
mg/dL and 5.2 ± 1.2 mg/dL before and after 6 months of
education, respectively) and in the Ca × P product levels
(61 ± 7.7 mg2/dL2 and 47 ± 11 mg2/dL2 before and af-
ter 6 months of counseling, respectively) was observed in
the group of patients who had received dietary counsel-
ing and educational tools, compared with a control group
of patients (phosphorus: 7.2 ± 1.3 mg/dL and 6.7 ± 1.7
mg/dL before and after 6 months education, respectively;
Ca × P product: 62 ± 9.6 mg2/dL2 and 60 ± 14.3 mg2/dL2
before and after 6 months of education, respectively).
However, dietary phosphorous restriction and
hemodialysis are often not effective in adequately
controlling serum phosphorous, and phosphate binders
have been routinely prescribed to reduce the intestinal
absorption of phosphorous. Various estimates of patient
compliance indicate that the side effects of constipation
and nausea may cause as many as one half of a dialysis
population to discontinue regular use of phosphate
binders. Although aluminum-based phosphate binders
have been effectively used in reducing levels of serum
phosphorus, the risk of toxicity due to aluminum absorp-
tion is high. Increased incidence of aluminum-induced
bone disease, osteomalacia, encephalopathy, and mi-
crocytic anemia seen in CKD patients has resulted
in abandoning the use of aluminum-based phosphate
binders [20].
Calcium-based phosphate binders have been effec-
tive in combination with vitamin D, and have replaced
aluminum-binders worldwide; calcium acetate is the
binder of choice in the United States, and calcium carbon-
ate is used extensively in Europe [21]. The efficacy and
cost effectiveness of calcium-based binders have been
outweighed by concern for the long-term safety of these
agents. These agents have a risk of metastatic calcifica-
tion, particularly if taken with vitamin D analogues, and
are prescribed when a high dialysate calcium concentra-
tion is employed. The major advantage of calcium-based
phosphate binders is their low cost, and long experience in
their use for “hyperacidity” with minimal toxicity to those
who have been treated daily with proprietary antacids for
a decade or longer.
However, the debate about the safety of calcium-based
phosphate binders continues. Treating dialysis patients
with these agents results in a higher oral calcium in-
take, conferring an additional risk of coronary calcifica-
tion and death. Goodman et al used EBCT to screen for
coronary-artery calcification in 39 young patients with
ESRD (mean age 19 years) compared with 60 normal in-
dividuals [22]. This study reports an increase in the mean
serum phosphorus concentration and the Ca × P prod-
uct in serum of ESRD patients with coronary calcifica-
tion. The daily intake of calcium-containing phosphate
binders was nearly twice as great in ESRD patients with
cardiac calcification as in those patients without calcifica-
tion. These observations suggest that the long-term expo-
sure to alterations in mineral metabolism seen in ESRD
patients, and the subsequent efforts to treat and correct
these alterations may contribute to coronary artery cal-
cification in young adults.
An alternative phosphate binder that is not aluminum-
or calcium-based is sevelmer hydrochloride, a quater-
nary amine anion exchange resin that binds phosphate
ions and releases hydrochloric acid [23]. A randomized
52-week “Treat-to-Goal ” trial compared sevelamer hy-
drochloride to two calcium-containing phosphate binders
in a group of 200 hemodialysis patients [24]. The primary
end point of this trial was to achieve Ca × P product tar-
get levels, and to estimate calcification of the coronary
arteries using a calcification score from EBCT measure-
ments. Both sevelamer hydrochloride and the calcium-
based phosphate binders provided equivalent control of
serum phosphorus. However, serum calcium concentra-
tion, hypercalcemia, and an increased absolute calcium
score in coronary arteries were seen in patients treated
with calcium, but not with sevelamer.
These data contrasted with those reported in the Cal-
cium Acetate Renagel Evaluation (CARE) study (dis-
cussed by Dr. Nolan in this supplement). The CARE
study compared the efficacy and safety of calcium acetate
and sevelamer hydrochloride in the treatment of hyper-
phosphatemia in CKD patients [25]. In this 8-week trial,
treatment with calcium acetate was found to be more
effective in controlling serum phosphorous and Ca × P
product levels than treatment with sevelamer hydrochlo-
ride. Side effects were similar for patients treated with
calcium acetate or sevelamer hydrochloride.
In a recent review, Coladonato et al suggest that the
warnings of putative dangers associated with calcium-
containing phosphate binders appear to be premature in
the context of risk versus benefits of calcium-containing
phosphate binders [26]. The need for prospective, ran-
domized control trials to examine the pathobiology of
coronary calcification in CKD and ESRD patients is
essential. Studies that examine differences in the rates
of calcification in calcium-containing and calcium-free
phosphate binders, when controlling hyperphosphatemia
and hyperparathyroidism, would help resolve some of
these issues. A recommendation is made on the im-
portance of having outcome-based trials, using clini-
cal cardiac events as primary outcomes—along with
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thorough scientific research—before abandoning the use
of calcium-containing phosphate binders.
Restoring vitamin D and calcium levels
In an attempt to restore vitamin D levels, patients with
CKD are also treated with vitamin D derivatives. Until
recently, high doses of oral calcium supplements and/or 1-
a-hydroxylated vitamin D derivatives were the mainstay
of treatment of secondary hyperparathyroidism in CKD.
However, these treatments may not be well tolerated due
to the associated vascular and soft tissue calcification. An
association between vascular calcification and the use of
vitamin D therapy has been reported [27]. To circumvent
the adverse effects observed with vitamin D therapy, cal-
cimimetic agents are under development.
Calcimimetics
Calcimimetic agents modulate the activity of the
calcium-sensing receptor, and result in profound reduc-
tions in levels of circulating PTH. Additionally, these
agents result in decreases in serum calcium, phospho-
rus, and Ca × P product [28]. A recent study with the
second generation calcimimetic agent, cinacalcet HCl,
confirms that this agent represents a safe and effective
novel therapy with the potential to dramatically alter the
treatment and complications associated with secondary
hyperparathyroidism in patients on dialysis. Block et al
report the observations from two randomized double-
blind placebo trails evaluating the safety and effective-
ness of cinacalcet in hemodialysis patients who were
unable to control the secondary hyperparathyroidism
despite standard treatment [29]. Patients received
cinacalcet (N = 371) or placebo (N = 370) for a period of
26 weeks. The once-daily dosage was increased from 30
mg to 180 mg to achieve intact PTH levels of 250 pg/mL or
less. The primary end point was percent of patients with
PTH levels in this range during a 14-week efficacy assess-
ment. Mean PTH levels decreased 43% in patients receiv-
ing cinacalcet compared with controls (P < 0.001). The
Ca × P product decreased 15% in the cinacalcet treated
group compared with the placebo control group (P <
0.001) [29]. The development of calcimimetic agents may
dispel the controversy that has prevailed over the use of
calcium-based phosphate binders in conjunction with vi-
tamin D therapy.
CONCLUSION
Hypocalcemia, hyperphosphatemia, and reduced vita-
min D seen in patients with CKD are associated with
elevated levels of PTH and secondary hyperparathy-
roidism. The clinical consequences of increased PTH
levels include renal osteodstrophy, systemic and arterial
effects that increase mortality. It is important to control
serum phosphorus levels in dialysis patients because hy-
perphosphatemia and the elevated Ca × P correlate with
cardiovascular mortality and bone disease. Currently,
both sevelamer and calcium-containing phosphate
binders (calcium acetate and calcium carbonate) are ac-
ceptable first-line therapeutic agents in the treatment of
ESRD patients with hyperphosphatemia. Cost-benefit
analysis, and the superior efficacy of calcium acetate
in controlling serum phosphorous, make it a treatment
choice for initial treatment of ESRD patients. Seve-
lamer hydrochloride, the noncalcium-, nonaluminum-
containing phosphate binder is the preferred treatment
choice for patients who develop persistent hypercal-
cemia during treatment with the calcium-based phos-
phate binders. This treatment, however, has the potential
risk of acid loading in ESRD patients.
Sevelamer hydrochloride and calcium acetate are the
only two drugs approved by the FDA in the treatment of
hyperphosphatemia in dialysis patients. Ongoing studies
with calcimimetic agents will offer alternate therapeutic
choices for patients with CKD.
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